New CAR-T therapy aims to keep High-Risk leukemia in remission

NCT ID NCT07575971

Recruiting now Disease control Sponsor: Liping Dou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and effectively prevent the cancer from coming back. About 30 participants will receive the CAR-T cells after a short course of chemotherapy, and researchers will monitor them for side effects and outcomes like survival and relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD22/CD19 dual-target CAR-T cells
What this could lead to: If successful, this could provide a more effective consolidation therapy for high-risk B-ALL, potentially reducing relapse rates and improving long-term survival after initial remission.
What could go wrong: This is an early-phase (1/2) study with only 30 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and neurotoxicity, and the dual-target approach is still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.